Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies and small-molecule treatments for eye diseases, primarily inherited retinal diseases (IRDs) and other ophthalmic conditions. Its core pipeline includes seven adeno-associated virus (AAV)-based gene therapy programs targeting various genetic forms of blindness, along with licensed and in-house developed small-molecule therapies for conditions such as mydriasis reversal, presbyopia, and diabetic retinopathy. The company generates revenue primarily through partnership and licensing agreements, including a global deal with Viatris for an ophthalmic solution that provides upfront payments, milestone fees, and tiered royalties, while its gene therapies are funded through research partnerships with foundations and government agencies, with future revenue dependent on clinical success and commercialization by partners or through its own efforts.